Current Status of Solid Tumor Treatment in China (2026): A Comprehensive Guide for International Patients Seeking Cancer Care in China

By:DengYue International Business Division

As global cancer treatment rapidly evolves toward precision medicine, personalized therapy, and long-term disease control, China has emerged as one of the world’s most dynamic innovation centers in solid tumor treatment. Supported by a massive patient population, accelerated drug approval pathways, extensive clinical trial networks, and increasingly mature multidisciplinary treatment (MDT) systems, China has reached internationally advanced — and in some areas leading — levels in the treatment of lung cancer, gastric cancer, liver cancer, breast cancer, colorectal cancer, and other major solid tumors.

For international patients facing advanced or treatment-resistant cancers, China offers not only broader access to innovative therapies and significantly lower treatment costs, but also earlier opportunities to access cutting-edge therapeutic strategies that may still be limited elsewhere.

DengYue serves as a professional bridge connecting international patients with China’s leading hospitals, oncology specialists, and innovative therapies. Through compliant pharmaceutical sourcing, medical coordination, and cross-border healthcare support, DengYueMed helps overseas patients efficiently and safely access high-quality cancer treatment resources in China while overcoming geographic and informational barriers.

I. China’s Solid Tumor Treatment Landscape and Key Developments in 2026

China has one of the world’s highest numbers of newly diagnosed cancer cases each year. However, driven by the “Healthy China” national strategy, accelerated NMPA approval mechanisms, and the rapid expansion of domestic biotech innovation, outcomes for solid tumor patients continue to improve significantly.

Between 2025 and 2026, China’s solid tumor treatment landscape has been shaped by three major trends:

1. CAR-T Cell Therapy Expanding Into Solid Tumors

For many years, CAR-T therapy was primarily used for hematologic malignancies. Chinese research teams are now leading major breakthroughs in applying CAR-T to solid tumors.

The world’s first Claudin18.2 (CLDN18.2)-targeted CAR-T therapy for solid tumors — satri-cel / CT041 — has completed pivotal clinical trials and submitted its marketing application to China’s National Medical Products Administration (NMPA).

This therapy is mainly designed for advanced gastric cancer and gastroesophageal junction cancer. Phase II randomized studies demonstrated meaningful improvements in both progression-free survival (PFS) and overall survival (OS), offering new hope to patients who have exhausted conventional treatment options.

Research led by Professor Shen Lin’s team at Peking University Cancer Hospital and multiple Chinese cancer centers has already been published in leading international medical journals.

2. Rapid Expansion of Immunotherapy and ADC Combinations

China has approved more than 20 PD-1/PD-L1 inhibitors, many of which are now widely combined with chemotherapy, anti-angiogenic therapy, and targeted therapy as standard first-line or second-line treatment for advanced solid tumors.

Antibody-drug conjugates (ADCs) targeting HER2, TROP2, CLDN18.2, Nectin-4, and other biomarkers are also developing rapidly and showing strong efficacy in breast cancer, lung cancer, gastric cancer, and additional tumor types.

3. Precision Medicine and Multimodal Treatment Integration

Advanced biomarker testing has become increasingly routine in China, including:

● NGS genomic sequencing

● Liquid biopsy

● PD-L1 testing

● MSI-H/dMMR detection

● HER2 analysis

● CLDN18.2 biomarker testing

At the same time, minimally invasive interventional therapies such as TACE, tumor ablation, radioactive seed implantation, proton therapy, heavy ion therapy, and integrative rehabilitation approaches continue to improve long-term disease control and quality of life.

These developments have positioned China as a highly competitive destination for international patients seeking second-line, later-line, or experimental treatment opportunities.

II. Why International Patients Are Choosing China for Solid Tumor Treatment

Several factors are driving the growing interest in China among overseas cancer patients:

Faster Access to Innovative Therapies

Many therapies that are still undergoing Phase III trials or pending approval in Europe or the United States are already available in China through clinical studies, expanded access programs, or commercial approval.

China’s regulatory approval process has become significantly faster in recent years.

Cost Advantages

Comparable treatment plans in China often cost only 30%–60% of what patients may pay in Western countries.

This cost advantage is particularly significant for:

● CAR-T therapy

● Long-term immunotherapy

● Targeted therapy

● Hospitalization and supportive care

Extensive Clinical Trial Networks

China now hosts one of the world’s largest oncology clinical trial ecosystems. Major cancer centers routinely participate in international multicenter studies and early-phase innovative therapy programs.

Comprehensive International Patient Services

Many leading hospitals now provide:

● International wards

● Multilingual support

● MDT consultation systems

● Dedicated international patient coordination

● Long-term follow-up management

DengYueMed assists international patients in accessing updated treatment information, remote MDT consultation pathways, and compliant clinical trial coordination support.

III. Recommended Cancer Hospitals in China for Solid Tumor Treatment

Below are some of the most frequently referenced cancer hospitals among international patients in 2026, based on national rankings, specialty reputation, and oncology research strength.

National Cancer Center / Cancer Hospital Chinese Academy of Medical Sciences (Beijing)

One of Asia’s largest and most influential cancer centers.

Particularly strong in:

● Lung cancer

● Esophageal cancer

● Gastric cancer

● Breast cancer

● Radiation oncology

● Precision oncology

The hospital operates advanced radiotherapy facilities and mature international patient services.

Peking University Cancer Hospital (Beijing)

A national leader in gastrointestinal cancers, especially gastric cancer.

The hospital is also one of China’s key research centers for CLDN18.2 CAR-T and solid tumor cellular therapy.

Professor Shen Lin’s team is internationally recognized for work in:

● Gastrointestinal oncology

● Precision medicine

● Immunotherapy

● Cellular therapy

The center is highly relevant for patients exploring advanced CAR-T options.

Fudan University Shanghai Cancer Center (Shanghai)

One of the leading oncology institutions in Eastern China.

Strong specialties include:

● Breast cancer

● Colorectal cancer

● Pancreatic cancer

● Head and neck tumors

The hospital is known for advanced minimally invasive surgery, mature MDT systems, and strong translational research capabilities.

Sun Yat-sen University Cancer Center (Guangzhou)

A major oncology center in Southern China.

Especially experienced in:

● Liver cancer

● Nasopharyngeal carcinoma

● Lung cancer

● Colorectal cancer

The hospital is also recognized for advanced liver cancer interventional therapies and integrated multidisciplinary management.

Its international patient services continue to expand rapidly.

Other Important Cancer Centers

Additional hospitals with strong oncology capabilities include:

● Tianjin Medical University Cancer Institute & Hospital

● West China Hospital

● Jiangsu Cancer Hospital

Most of these institutions operate international departments or VIP medical centers capable of providing:

● English-language medical evaluation

● Remote consultations

● Personalized care coordination

DengYueMed helps match patients with the most appropriate hospitals and oncology teams based on tumor type, disease stage, biomarker profile, and prior treatment history.

IV. Current Treatment Status of Major Solid Tumors in China

Non-Small Cell Lung Cancer (NSCLC)

Precision targeted therapy for EGFR, ALK, KRAS, and other driver mutations, combined with immunotherapy, has significantly improved survival outcomes.

Gastric Cancer and Pancreatic Cancer

CLDN18.2-targeted therapy, HER2-directed therapy, and CAR-T programs are creating new options for advanced-stage patients.

Liver Cancer

Combination approaches using TKIs, immunotherapy, TACE, and ablation are increasingly mature. Some patients may achieve successful downstaging for surgery.

Breast Cancer

HER2-positive, HR-positive, and triple-negative breast cancer patients now have broader access to:

● ADC therapies

● CDK4/6 inhibitors

● PARP inhibitors

● Precision targeted regimens

Colorectal Cancer

Immunotherapy has shown especially strong outcomes in MSI-H/dMMR patients, while targeted therapies continue evolving rapidly.

V. Practical Guidance for International Patients Seeking Cancer Treatment in China

1. Prepare Medical Records in Advance

Patients should organize:

● Pathology reports

● Imaging studies

● Treatment history

● Genomic testing results

English and Chinese bilingual documentation is strongly recommended.

2. Match the Appropriate Hospital and Specialist

Hospital selection should be based primarily on:

● Tumor type

● Disease stage

● Molecular profile

● Treatment goals

3. Plan Visa and Logistics Early

Patients should prepare:

● Medical visas

● Accommodation arrangements

● Transportation

● Caregiver support

4. Long-Term Treatment Management

International patients should also plan for:

● Cross-border medication continuity

● Follow-up imaging

● Side-effect management

● Remote communication after returning home

5. Final Treatment Decisions Require Physician Evaluation

All treatment plans must ultimately be determined by qualified oncology specialists after full clinical assessment.

Conclusion

China’s solid tumor treatment landscape in 2026 is entering a critical stage of transition from global “fast follower” to, in some areas, international leader.

An increasing number of international patients are extending survival and improving quality of life through access to China’s advanced oncology therapies, innovative clinical research, and rapidly evolving multidisciplinary cancer systems.

DengYueMed remains committed to serving as a trusted professional bridge between international patients and China’s high-quality oncology resources.

Beyond compliant access to innovative anti-cancer therapies and international pharmaceutical support, DengYueMed helps patients efficiently connect with leading hospitals, expert physicians, and clinical trial opportunities to ensure that every patient can access the most appropriate personalized treatment strategy at the right time.

If you or your family are facing the challenges of solid tumor treatment, please visit https://dengyuemed.com/ or contact us for personalized consultation support. Our professional team can assist with preliminary medical evaluation, hospital recommendations, and cross-border treatment coordination, helping make the journey toward advanced cancer care in China clearer, safer, and more efficient.

This article is based on publicly available clinical research, CSCO guidelines, and authoritative hospital ranking data. It is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. All medical decisions should be made in consultation with qualified physicians through authority medical channels.